COMPARATIVE ANALYSIS OF THE RESULTS OF 24-HOUR CARDIO MONITORING IN PATIENTS WITH VENTRICULAR RHYTHM DISORDERS AND TYPE II DIABETES UNDER THE INFLUENCE OF TWO MODES OF METABOLITOTROPIC THERAPY

  • Г. А. Игнатенко ФГБОУ ВО «Донецкий государственный медицинский университет имени М. Горького» МЗ РФ, Донецк
  • И. В. Мухин ФГБОУ ВО «Донецкий государственный медицинский университет имени М. Горького» МЗ РФ, Донецк
  • К. С. Зубрицкий ФГБОУ ВО «Донецкий государственный медицинский университет имени М. Горького» МЗ РФ, Донецк
  • В. Р. Миминошвили ФГБОУ ВО «Донецкий государственный медицинский университет имени М. Горького» МЗ РФ, Донецк

Abstract

The aim of the study: to conduct a comparative analysis of changes in 24-hour cardiac monitoring parameters under the influence of two modes of metabolitotropic therapy in patients with ventricular arrhythmias against the background of type II diabetes mellitus (type II diabetes mellitus).
The study included 129 patients with ventricular arrhythmias and type II diabetes. Using a random sampling method, project participants were distributed into three observation groups. Patients of group 1 received a beta-blocker and amiodarone. Representatives of group 2 received the same therapy, but meldonium was used as an additional component. Patients in group 3 were treated with a beta-blocker, amiodarone and trimetazidine. Cardiac monitoring was performed at baseline, 6 months, and 1 year.
Statistical processing of the actual research results was carried out using the statistical software package Statistica 6.0.
In patients with type II diabetes with ventricular cardiac arrhythmias, tachycardia syndrome occurred, as well as clinically significant and painless signs of myocardial ischemia. Ischemia is one of the significant factors of arrhythmic syndrome in diabetes. Cardio protective therapy with long-term use of metabolitotropic drugs is a pathogenetically substantiated direction of complex treatment aimed at reducing the risk of life-threatening rhythm disturbances and cardiovascular events. Preference when carrying out complex treatment in patients with type II diabetes with ventricular arrhythmic syndrome should be given to trimetazidine, since it has demonstrated a more pronounced anti-ischemic effect, faster than that of meldonium.

References

1. Крутиков Е.С., Цветков В.А., Чистякова С.И. Особенности нарушений сердечного ритма и оценка их факторов риска у больных сахарный диабетом 2-го типа. Таврический меди-ко-биологический вестник 2023; 3: 58-64.
2. Шурдумова М.Г. Патогенетические предпосылки электрической нестабильности миокар-да у больных артериальной гипертензией и сахарным диабетом. Медицинский вестник юга России 2015; 3: 8-17.
3. Татарченко И.П., Позднякова Н.В., Денисова А.Г., Морозова О.И. Клинико-инструментальный анализ желудочковых нарушений ритма при диастолической сердеч-ной недостаточности у больных сахарным диабетом 2-го типа. Проблемы эндокриноло-гии 2015; 2: 21-27.
4. Fernandes G.C., Fernandes A., Cardoso R. et al. Association of SGLT2 inhibitors with arrhyth-mias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098-1105. doi: 10.1016/j.hrthm.2021.03.028
5. Agarwal G., Singh S.K. Arrhythmias in Type 2 Diabetes Mellitus. Indian J. Endocrinol. Metab. 2017; 21(5): 715-718. doi: 10.4103/ijem.IJEM_448_16
6. Li R., Tang X., Jing Q. et al. The effect of trimetazidine treatment in patients with type 2 diabe-tes undergoing percutaneous coronary intervention for AMI. Am. J. Emerg. Med. 2017; 35(11): 1657-1661. doi: 10.1016/j.ajem.2017.05.024
7. Belardinelli R., Cianci G., Gigli M. et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. Car-diovasc Pharmacol. 2008; 51(6): 611-5. doi: 10.1097/FJC.0b013e31817bdd66
8. Thrainsdottir I.S., von Bibra H., Malmberg K., Rydén L. Effects of trimetazidine on left ventric-ular function in patients with type 2 diabetes and heart failure. J. Cardiovasc. Pharmacol. 2004; 44(1): 101-8. doi: 10.1097/00005344-200407000-00014
9. Weidner K., Behnes M., Schupp T. et al. Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias. Cardiovasc Diabetol. 2018; 17(1): 125. doi: 10.1186/s12933-018-0768-y
10. Chen C., Wang W., Zhou W. et al. Nocturnal ventricular arrhythmias are associated with the se-verity of cardiovascular autonomic neuropathy in type 2 diabetes. J. Diabetes. 2019; 11(10): 794-801. doi: 10.1111/1753-0407.12908
11. Sarapultsev P., Yushkov B., Sarapultsev A. Prevalence of arrhythmias in patients with type 2 diabetes and the role of structural changes in myocardium in their development. Diabetes Metab Syndr. 2017; 11 Suppl. 2: 567-576. doi: 10.1016/j.dsx.2017.04.006
12. Amaral N., Okonko D.O. Metabolic abnormalities of the heart in type II diabetes. Diab. Vasc. Dis. Res. 2015; 12(4): 239-48. doi: 10.1177/1479164115580936
13. Fi Z., Kovács G., Szentes V. Role of trimetazidine in the treatment of diabetic microangiopathy in ischaemic heart disease. Orv. Hetil. 2015; 156(19): 765-8. doi: 10.1556/650.2015.30160
14. Jungen C., Scherschel K., Flenner F. et al. Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. Am. J. Physiol. Heart. Circ. Physiol. 2019; 317(6): 1328-1341. doi: 10.1152/ajpheart.00249.2019
Published
2023-12-25
How to Cite
ИГНАТЕНКО, Г. А. et al. COMPARATIVE ANALYSIS OF THE RESULTS OF 24-HOUR CARDIO MONITORING IN PATIENTS WITH VENTRICULAR RHYTHM DISORDERS AND TYPE II DIABETES UNDER THE INFLUENCE OF TWO MODES OF METABOLITOTROPIC THERAPY. University Clinic, [S.l.], n. 4 (49), p. 5-10, dec. 2023. ISSN 1819-0464. Available at: <http://journal.dnmu.ru/index.php/UC/article/view/2015>. Date accessed: 16 oct. 2025.
Citation Formats
Issue
No 4 (49) (2023): UNIVERSITY CLINIC
Section
Оригинальные исследования